Behind Brexu-cel's Development in Relapsed/Refractory B-Cell ALL

Evandro D. Bezerra, MD, the Ohio State Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, discusses brexucabtagene autoleucel (Tecartus; brexu-cel) and how it has been developed for the treatment of patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) thus far.

Outcomes of brexu-cel in a broad real-world patient population of patients with R/R B-ALL were recently examined and showed to be consistent with findings from ZUMA-3 (NCT02614066), a trial which supported the FDA’s approval of the agent in 2021.

According to real-world findings, while there were differences between the patient populations in the real-world and clinical settings, the efficacy of brexu-cel in this real-world analysis was consistent with what was observed in the ZUMA-3 clinical trial.

Transcription:

0:09 | Brexu-cel is a CD19 [chimeric antigen receptor (CAR)] T-cell therapy for patients with relapsed/refractory B-cell ALL, and also other B-cell malignancies. [These] data show the real-world outcomes of brexu-cel since it was approved as a standard-of-care for this patient population. [These data] show that the brexu-cel is highly effective in the real-world setting, consistent with the data from the ZUMA-3 clinical trial, despite the significant difference between the patient populations in the ZUMA-3 clinical trial and the real-world population.

0:47 | The ZUMA-3 clinical trial was the pivotal trial that led to the approval of brexu-cel itself for relapsed/refractory B-cell ALL. On that trial, patients with relapsed/refractory B-cell ALL received brexu-cel itself, and they had high efficacy, with [complete response (CR)] rates of 71% and patients that responded had a median overall survival of 47 months.

REFERENCE:

Bezerra E, Itani T, Wudhikarn K, et al. Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) adult B-cell acute lymphoblastic leukemia (B-cell ALL): evidence from the CIBMTR registry. Blood. 2023;142(suppl 1):1029. doi:10.1182/blood-2023-174543